4.7 Article

RNA-binding motif protein 10 represses tumor progression through the Wnt/β-catenin pathway in lung adenocarcinoma

Journal

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
Volume 18, Issue 1, Pages 124-139

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/ijbs.63598

Keywords

RBM10; progression; Wnt/beta-catenin pathway; CTNNBIP1; lung adenocarcinoma

Funding

  1. National Natural Science Foundation of China [81872396, 81672931]
  2. National Cancer Center of China Climbing Fund [NCC201808B017]
  3. Shenzhen Science and Technology Program [RCJC20200714114436049]
  4. Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center/ShenZhen Cancer Hospital Research Project [SZ2020ZD006]
  5. Hei Long Jiang Postdoctoral Foundation [LBH-Z18196]
  6. Post graduate research and practice innovation project of Harbin Medical University [YJSKYCX2019-58HYD]

Ask authors/readers for more resources

RBM10 functions as a tumor suppressor in LUAD by positively regulating the expression of CTNNBIP1 and inactivating the Wnt/beta-catenin pathway.
RNA-binding motif protein 10 (RBM10), one of the members of the RNA-binding protein (RBP) family, has a tumor suppressor role in multiple cancers. However, the functional role of RBM10 in lung adenocarcinoma (LUAD) and the underlying molecular mechanism remains unclear. In this study, we observed that RBM10 is significantly downregulated in LUAD tissues compared with normal tissues. Low RBM10 expression is significantly associated with poor outcome of LUAD patients. In vitro and in vivo experiments show that RBM10 inhibits cell proliferation, metastasis and EMT progression in LUAD. Mechanistically, we demonstrate that RBM10 interacts with beta-catenin interacting protein 1 (CTNNBIP1) and positively regulates its expression, disrupting the binding of beta-catenin to the transcription factor TCF/LEF, thereby inactivating the Wnt/beta-catenin pathway. In conclusion, this is the first study reporting the role of RBM10 in suppressing LUAD progression at least via partly inactivating the Wnt/beta-catenin pathway, which provides new insights into the tumorigenesis and metastasis of LUAD. Thus, RBM10 may be a promising new therapeutic target or clinical biomarker for LUAD therapy in the future.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available